The Effect of Persistence and Compliance of Antiplatelet and Dyslipidemia Agents on Cardiovascular Outcomes in Real World Patients Undergoing Percutaneous Coronary Intervention
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 47,291
- 试验地点
- 1
- 主要终点
- Incidence density of MACE
研究概览
简要总结
A nationwide retrospective cohort study. To investigate the real world medication compliance and the relation with clinical outcomes.
The persistence and compliance to dual anti-platelet therapy(DAPT) and dyslipidemia agents are important for the patients undergoing percutaneous coronary intervention. But, the discontinuation and compliance rate are unknown in the real world setting.
详细描述
A nationwide retrospective cohort study. The persistence and compliance to dual anti-platelet therapy(DAPT) and dyslipidemia agents are important for the patients undergoing percutaneous coronary intervention. The discontinuation and uncompliance may increase a risk. But, the discontinuation and compliance rate are not well known in the real world patients undergoing bare metal stents(BMS) and drug eluting stents(DES) insertion.
To investigate the real world medication compliance and the relation with clinical outcomes, administrative claim data was extracted from the Korean National Healthcare Insurance(KNHI) database.
All Korean patient date undergoing PCI from January 1, 2011 to December 2011 is extracted. 5 year clinical outcomes are investigated.
Primary outcomes are the MACE including all-cause death, revascularization, critically ill status, and stroke) classified by the medication compliance. Medication complinace is measured by proportion of days covered(PDC)
Secondary outcomes are the patterns of medication persistence and its outcomes to understand critical points.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Retrospective
入排标准
- 接受健康志愿者
- 否
入选标准
- •All claim of percutaneous coronary intervention using stent in the National Healthcare Insurance Service of Korea between January 1st 2011 and December 31st, 2011
排除标准
- •No use of stents
- •Stent not classified into DES or BMS
- •Use of DES and BMS together at the same initial day
结局指标
主要结局
Incidence density of MACE
时间窗: 5 years
5 year incidence densities of a major adverse clinical events(MACEs) consisting of all-cause death, revascularization, critically ill status and stroke.
次要结局
- Compliance defined as a proportion of days covered (%)(6 month)
研究者
Jin-Ho Choi
MD, PhD, Professor
Samsung Medical Center